We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Camille Samuels is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family. Her investment interests span early-stage biotech to medical devices to consumer health. For instance, she serves on the board of directors of Unity biotech (UBX), a public longevity company — and is an observer on the board at Corvidia, a private cardiorenal company. She stepped off the board of RegenXBIO (RGNX) a year after it went public — and from Spirox after its acquisition by Entellus (and Stryker).
Prior to Venrock, Cami spent over a decade as a Managing Director at Versant Ventures, a leading life sciences venture capital firm. While at Versant, Cami seeded Kythera (makers of Kybella) and served on the company’s board through its IPO and eventual sale to Allergan for $2.1 B. In addition, she served as a board member or a board observer on many other innovative healthcare companies including Achaogen (AKAO), Carmenta (acq. by Progenity), Fluidigm (FLDM), Genomic Health (GHDX), Novacardia (acquired by Merck), ParAllele (acq. by Affymetrix), and Syrrx (acq. by Takeda).
This speaker's sessions: